A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients.
暂无分享,去创建一个
M. J. van de Vijver | H. Bartelink | L. Boersma | M. de Maaker | M. Hoogstraat | E. van Werkhoven | F. van der Leij | P. Elkhuizen | A. Fourquet | P. Poortmans | S. Bosma
[1] H. Bartelink,et al. A signature that may be predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences. , 2020, International journal of radiation oncology, biology, physics.
[2] Nikhil Wagle,et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Fernö,et al. Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. V. van Diest,et al. Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Pierce,et al. Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review. , 2016, JAMA oncology.
[6] M. Reinders,et al. RUBIC identifies driver genes by detecting recurrent DNA copy number breaks , 2016, Nature Communications.
[7] R. Finn,et al. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers , 2016, Breast Cancer Research.
[8] Felix Y. Feng,et al. Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer , 2015, Clinical Cancer Research.
[9] H. Bartelink,et al. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis , 2014, Breast Cancer Research and Treatment.
[10] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[11] M. Dunning,et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.
[12] A. Frigessi,et al. Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort , 2014, Clinical Cancer Research.
[13] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[14] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] V. Tjan-Heijnen,et al. Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. , 2013, European journal of cancer.
[16] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[17] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[18] Emmanuel Barillot,et al. Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women , 2012, Clinical Cancer Research.
[19] C. Sotiriou,et al. Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling , 2012, Clinical Cancer Research.
[20] P. Watson,et al. True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy. , 2011, International journal of radiation oncology, biology, physics.
[21] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Adam B. Olshen,et al. Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles , 2011, Bioinform..
[23] V. Tjan-Heijnen,et al. Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years , 2011, Breast Cancer Research and Treatment.
[24] T. Nielsen,et al. Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Paik,et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Aaron R. Quinlan,et al. BIOINFORMATICS APPLICATIONS NOTE , 2022 .
[27] M. J. van de Vijver,et al. Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients , 2009, Clinical Cancer Research.
[28] A. Bleyer,et al. Breast cancer before age 40 years. , 2009, Seminars in oncology.
[29] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[30] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Barbara L. Smith,et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Carsten Peterson,et al. Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy , 2008, Breast Cancer Research.
[33] Emmanuel Barillot,et al. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. , 2008, Journal of the National Cancer Institute.
[34] Daniel Birnbaum,et al. Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.
[35] Howard Y. Chang,et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling , 2006, Breast Cancer Research.
[36] D. Birnbaum,et al. BMC Cancer , 2003 .
[37] M. J. van de Vijver,et al. Gene Expression Profiles of Primary Breast Carcinomas from Patients at High Risk for Local Recurrence after Breast-Conserving Therapy , 2006, Clinical Cancer Research.
[38] M. Wigler,et al. Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.
[39] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[40] L Collette,et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? , 2003, European journal of cancer.
[41] S. Singletary,et al. Classifying local disease recurrences after breast conservation therapy based on location and histology , 2002, Cancer.
[42] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] J. Peterse,et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[45] Richard Sylvester,et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. , 2000, Journal of the National Cancer Institute.
[46] M. J. van de Vijver,et al. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. , 1998, International journal of radiation oncology, biology, physics.
[47] D. Horsfall,et al. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer , 1997, Oncogene.
[48] E. van Limbergen,et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. , 2015, The Lancet. Oncology.
[49] H. Bartelink,et al. Quality indicators for breast cancer: revisiting historical evidence in the context of technology changes. , 2012, Seminars in radiation oncology.
[50] Bryan Langholz,et al. Risk set sampling in epidemiologic cohort studies , 1996 .